They proposed that the antagonistic relationship between NOTCH1 and BCR-ABL in CML suggests a combined inhibition of NOTCH1 and BCR-ABL may provide superior clinical response over tyrosine-kinase inhibitor monotherapy. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.